Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Free Cash Flow (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Free Cash Flow for 6 consecutive years, with -$20.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 34.43% to -$20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$111.1 million, a 20.07% increase, with the full-year FY2025 number at -$111.1 million, up 20.07% from a year prior.
  • Free Cash Flow was -$20.9 million for Q4 2025 at Caribou Biosciences, up from -$23.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $20.3 million in Q1 2021 to a low of -$38.1 million in Q1 2024.
  • A 5-year average of -$23.5 million and a median of -$23.1 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 210.37% in 2022, then skyrocketed 34.43% in 2025.
  • Caribou Biosciences' Free Cash Flow stood at -$22.1 million in 2021, then fell by 15.57% to -$25.5 million in 2022, then rose by 15.66% to -$21.5 million in 2023, then crashed by 48.09% to -$31.9 million in 2024, then surged by 34.43% to -$20.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Free Cash Flow are -$20.9 million (Q4 2025), -$23.7 million (Q3 2025), and -$28.7 million (Q2 2025).